Embed Size (px)
Citation preview
Copyr
O
Rob rob@
NT COM
Pharcompcommuponencauniquplatfocanccanc
KEY
Price
52 W
Est. S
Mark
3 Mo
Exch
COM
Phar1251Silve
WebsPhonEma
right © Goldma
Orphan D
Goldman @goldmanre
PHAT Price Tar
MPANY SN
rmaCyte Biotpany focusemercialize tren a propapsulation tecue and pateorm upon wer, includinger, and diabe
Y STATIST
e as of 3/25/1
Week High – L
Shares Outst
ket Capitalizat
o Avg. Vol.
hange
MPANY INF
rmaCyte Biot0 Prosperity
er Spring MD 2
site: http://wwne: 917.595il: info@Ph
an Small Cap R
PDrug Sta
esearch.com
ARMACYrget: $0.45,
NAPSHOT
tech is a clind on develatments for c
prietary cellhnology know
ented technowhich treatme
g advancedetes are being
ICS
5
Low
tanding
tion
FORMATIO
tech, Inc. Drive, Suite 320904
ww.PharmaCy5.2850 harmaCyteBio
Research, 2015
PHARMatus and
YTE BIOLT Price T
nical stage boping and
cancer and dialulose-based wn as Cell-in-ology will beents for seve, inoperable
g built.
$0.
$0.493
70
$8
2,01
OT
ON
310
yteBiotech.co
otech.com
www.gold5
MACYTd Upcom
OTECH, ITarget $1.80
biotechnologypreparing toabetes based
live cel-a-Box®. Thise used as aeral types ofe pancreatic
.1145
3 - $0.095
7.8M
1.0M
15,000
TCQB
om
dmanresearch.c
TE BIOming Mil
NC. (OT0
y o d l s a f c
INV
Pharcomcouldiffebillio
The has the pancthe dosemajoas a and
PMCprogserieCommilesthe tdebilengathe Box®as br
BaseanalundepotediabeothetechntypicSpecand
Invest
com
OTECH,lestones
TCQB – Rati
VESTMENT
rmaCyte Biompany whos
ld emerge aerent types oons of dollar
Company’s recently beFDA for thecreatic cancchemotherae normally or boost to PM
key player invalidates the
CB has agress over tes of clinic
mpany’s prstones includtreatment of litating symptaged in the sCannabis pla® technology rain cancer.
ed on our lysis alone,ervalued andntial technoletes, a disear forms of nology and
cal oncology culative Buy a long term ta
tment and O
COM
, INC. s to Driv
PMCB –ing: Specul
T HIGHLIGH
otech is an ise therapeutas the go-to of cancers anrs in market o
flagship teceen granted e treatment cer when usapy drug ifos
given. This MCB’s develon the pancreaCell-in-a-Box
achieved ethe past ye
cal trials in rofile and de mid-stage pancreatic ctoms, and fostudy of canant) in comb
y as treatmen
pancreatic , PMCB’s d grossly ovlogy portabilase affecting cancer, the PCMB are treatment enwith a near arget price of
CompanyOpportunity
PANY R
ve Stock
Ma
– $0.1145lative Buy
HTS
nnovative btic technolotreatment o
nd diabetes opportunity.
chnology, CeOrphan Druof advanced
sed in combsfamide at odesignation
opment effortatic cancer trex® technology
enviable deear and the
2015 shouits valua
and precliniccancer and itsr diabetes. P
nnabinoids (cbination with ts for deadly
treatment shares app
verlooked. Coity into the millions with true future likely far grtity. We rate term price ta
f $1.80.
y Researchy Research
REPORT
Page 1 of 17
k Price
arch 26, 2015
5)
iotechnologyogy platformof choice forepresenting
ell-in-a-Box®ug Status byd, inoperablebination withone-third theserves as a
s, its standingeatment arenay.
evelopmentalaunch of a
uld raise thetion. Thesecal studies fos serious and
Plus, PMCB isonstituents othe Cell-in-acancers such
peer grouppear greatlyonsidering the
treatment ono cure, andvalue of the
reater than athese share
arget of $0.45
7
5
y m r g
®, y e h e a g a
al a e e
or d s
of a-h
p y e of d e a s 5
Copyr
NE
We PharupdaGiveevensharits cposit
Key
TH
In 19the jchar$1002014toolsfact, AmeThes
1 http
right © Goldma
EW NAM
initiated cormaCyte Bioates and arten the substnts ahead, wres are undeurrent and ftioning now
Investment
PMCB owtreatmenthe road.
Favorablfollowed
The highPMCB’s
Preclinicapart, by tleading CPMCB pr
A series substant
Managem“cannabiwhere th
With mulpeer grou
E LAY O
971, U.S. Prury is still o
rities, founda0-billion in fu4 was over $s in the canc
there are merican Cancese include im
p://www.cance
an Small Cap R
E, NEW
overage of otech, Inc. inicles on the antive opera
we deemed iervalued in lifuture activitthan a year
Points:
wns exclusivnt of choice f. e legacy andby the comm profile and pancreatic cal trials for athe leading aContract Resrofile and coof steps areial market opment is activnoids”) in coere are no stiple shots oup.
OF THE
resident Ricut on whethations, and unding resea$5 billion.1 O
cer fight, but multiple apprer Society hmmunothera
er.gov/cancer
Research, 2015
DIRECT
Nuvilex, Inc May 2011 wCompany, w
ational and dit was the rigght of the Cty and visibiago, when i
ve rights to afor multiple c
d updated remencement coveted Orp
cancer treatmabdominal caauthority on search Orgaould result ine in progresspportunity. vely engagedombination wsubstantially on goal we b
LAND
hard Nixon her or not wecompany in
arch and deOver the pasthere is still
roaches to cighlights thepy and targe
rtopics/factsh
www.gold5
TION, MA
c., the Comwith a Specuwe have notdevelopmenght time to p
Company’s inility on the ct traded muc
a technologycancers and
esults from eof a Phase 2
phan Drug dment. ancers usingpancreatic c
anization tha future, fast-
s that will lea
d in pursuingwith its Cell-ieffective tre
believe that P
proclaimed e are winninnvestments evelopment pst several dno single ap
cancer treatme most commeted therapy
eet/NCI/resea
dmanresearch.c
AJOR P
mpany’s namulative Buy rt published o
ntal progresspublish an uncreasingly gclinical trial fch higher.
y that could ediabetes, po
early- mid-st2b clinical tresignation w
g the Compacancer, Dr. Dt specializes-tracked trial
ad toward dia
g the use of n-a-Box® pl
eatments on PMCB’s stoc
a war on cang the battletargeting anprojects. Toecades, canpproved treament that mmon approacy.
arch-funding
Invest
com
PROGES
me prior torating. Althouon the Coms achieved oupdated repogrowing proffront. One
emerge as totentially wo
tage pancrearial in 2H15. was granted
any’s platformDaniel Von Hs in oncologyls. abetes clinic
compoundslatform techthe market.
ck is overloo
ancer. In thee. After all, nti-cancer reo emphasizencer screeniatment that cay be a parches in prac
tment and O
COM
SS
o its early ugh we publpany since over the pasort. Moreovefile in the mecould argue
the first univeorth billions i
atic cancer c by the FDA
m technologHoff, and cony. This subs
cal trials, wh
s from the Canology to tre
oked and und
e 40+ years the Nationa
esearch have this, the buing and prevcould be conrt of radiatioctice and un
CompanyOpportunity
PANY R
2015 namelished dozenthe first quast 12 monthser, we believedical comme that PMCB
ersal therapin annual sa
clinical trials
A in Decembe
gy were desinducted by Astantially rais
ich, in turn, r
annabis planeat deadly ca
dervalued, r
since that pal Cancer Insve likely speudget at thevention havensidered a “hn or chemotder develop
y Researchy Research
REPORT
Page 2 of 17
e change tons of reportsarter of 2014s, and futureve that thesemunity due toB is in bette
py and ales down
s will be
er, 2014 to
gned, in America’s ses the
represent a
nt (known asancers
relative to its
proclamationstitute (NCI)ent well ovee NCI for juse been hugeholy grail.” Intherapy. The
pment, today
7
o s, 4. e e o
er
s
n, ), r
st e n e y.
Copyr
“Doccellsthroutumo
“Immcanccells
Somcellssurvincresuchsincetrialstheirtreat
PH
A nucancI/II cendilive worldtechsamdisea
THE
This the bnot eplaceof tamadfromenab
2 http:/some 3 http8997
right © Goldma
ctors use ches. Usually, thugh the bodor to other pl
munotherapcer. Targetes…”.2
me of these as from spreaivability rateease the quh treatmentse the currens whose objr therapy for tment for mu
ARMAC
umber of yeacer and diabclinical trial tng in 2013, cell encapsdwide licennology, Celle technologase treatme
E CELL-IN-
patented livbody after eencapsulate ed into the b
argeted therae largely fro
m attack by thbles encaps
//www.cancerebody-you-kn
p://yahoo.bra72&type=sect&
an Small Cap R
emotherapy he drugs ardy in the blolaces in the
py is treatmeed therapy i
approachesading, promoes, in other ality of life,
s have recet overall relaectives are treatment. I
ultiple cance
CYTE BIO
ars ago, a cbetes. Multipto treat inopPhamaCyte
ulation techse to use l-in-a-Box®. gy in combints.3
A-BOX® T
ve-cell encanclosing thedrugs, but l
beads, or enapeutic moleom cellulosehe body's desulated cells
r.org/treatmennow-has-canc
nd.edgar-onli&TabIndex=2
Research, 2015
y to kill cancere given intooodstream, body.”
ent designedis treatment
, especially ote cell deat
cases, therin untreatabived Federaative state oto move alof successfulrs.
OTECH:
ompany nowple animal stperable pance Biotech acnology for tthe same t In 2014, th
ination with
TECHNOLO
apsulation tee cells insideive human ccapsulated,
ecules via ane a bio-inert,efense mechs to survive
nt/understandcer-cancer-tre
ine.com/displ2&dcn=00010
www.gold5
er cells. Theo a vein (orreaching ca
d to boost thethat targets
targeted theh, kill cells, rapies have ble or terminal Drug Admof cancer treaong the devl, we believe
: THE VI
w based in Studies and ccreatic canccquired exclthe developtechnology he Company
compound
OGY
echnology ene tiny beadscells that havthese cells
n innovative non-toxic, bhanisms. At e for long p
dingyourdiagneatment-quest
ayfilinginfo.as019687-15-00
dmanresearch.c
e term chemor IV) or theyancer cells t
e cancer patthe cancer
erapy, combetc. While sbeen desig
nal patients.ministration atment is po
velopmental e that PMCB
EW FRO
Singapore dclinical trials cer in the eausive, worldment of treato treat dia
y also acquis from con
nables the tabout the sve been genenable cont delivery sysbiocompatibthe same ti
periods of t
nosis/talkingations
spx?FilingID=0953&nav=1
Invest
com
otherapy refy’re taken bthat may ha
tient’s own icells and ca
bine treatmesome cancegned to incr. Some of t(FDA) approoor, there arpath to ulti
B could emer
OM 35,0
developed an were comparly-2000’s. dwide right tatments for abetes, usinired an exclu
nstituents of
targeted plaize of a pinhnetically engtinuous and/stem. The c
ble material me, the beatime, which
boutcancer/w
=10563865-10&src=Yahoo
tment and O
COM
fers to the usby mouth. Cave spread
mmune systauses less da
ent methodsers are treatarementally rhe companioval for there hundreds mately obtarge as the u
00 FEET
n approach pleted, includ
Following to use a pro
all forms ong the tradusive, worldf Cannabis f
cement of ahead. This pgineered. De/or controlledcapsules enthat protects
ads provide is a major
whensomeone
072-
CompanyOpportunity
PANY R
se of drugs Chemo drugs
(metastasize
tem to help famage to he
s in order to able and caraise survivoies that hav
eir treatmentof ongoing
ain FDA appniversal ther
T
to treat varyding a succea series of
oprietary celof cancer anemarked na
dwide licensefor the dev
almost any cplatform techepending on d productionnclosing the s the encapa microenvir advantage
eyouknowhas
y Researchy Research
REPORT
Page 3 of 17
to kill cances then traveed) from the
fight the ealthy
stop cancerry favorableor rates and
ve developedts. Howeverand pending
proval to userapy or go-to
ying forms oessful Phasetransactionslulose-based
nd exclusiveame for thee to use tha
velopment o
cell type intohnology does
the cell typen and releaselive cells aresulated cellsronment thae over othe
scancer/when
7
er el e
er e d d r, g e o
of e s d
e, e
at of
o s e e e s
at r
-
Copyr
encaovercellspropdista
By uinactothethe concdrug
The Cell-procencamedpolymThis dropdropanotpolymaroudeveresumm each10,0depeencaare t
PA
Gemsingl49,0Sincsold beenFDA 4 http 5 http 6 http
right © Goldma
apsulation ter 5 years ans are alive aperties. Theant locations
using the tetive chemothr applicationactivating c
centration ofgs right wher
encapsulatio-in-a-Box® t
cess. The apsulated aium that mer and s
suspensioplet-forming mplets fall intther polymermers intera
und each elops into a “lting in a sin diameter
h capsule u00 cells. T
ending uponapsulated anto be used.5
ANCREA
mzar® (also le agent for 00 people in
ce the gemciby Celgene
n the “gold sA in 2013. Ab
p://www.pharm
p://www.pharm
p://www.cance
an Small Cap R
echnologies.nd, when thand fully func
ese properties around the
chnology, itherapy drugns. In the caells are plaf active cancre they’re ne
on of living ctechnology i
live cere first suscontains a
sodium cellun is passemachine andto a solutior. Immediateact, a memdroplet. Th“shell” arounspherical car. For pancultimately coThis numben the size nd for what
ATIC CAN
known as gthe treatme
n the U.S. atabine thera
e (NASDAQ standard” forbraxane® is
macytebiotech
macytebiotech
er.org/cancer
Research, 2015
In fact. Ceawed, the cctioning. Thes are criticworld to trea
is possibles into active
ase of the draced as closcer fighting
eeded, the tu
cells using ths a multi-ste
ells to bspended in a proprietaulose sulfated through d the resultinon containinely, as the twmbrane formhis ultimatend the dropleapsule 0.7-0reatic canceontains aboer can diff
of the cepurpose the
NCER A
gemcitabineent for advaare diagnoseapy results a– CELG - N
r the treatmea nanoparti
h.com/live-ce
h.com/
r/pancreaticca
www.gold5
ell-in-a-Box®capsules areere is no otal for an exat patients.
e to create se ones, 2) prrug-convertinse to the simolecules a
umor.4 This
he ep be
a ary te. a
ng ng wo ms ely et,
0.8 er, out fer lls ey
AND TRE
), first approanced pancred with pancalone leave aNR) is now uent of advanicle formulat
ell-encapsulat
ancer/overview
Image
dmanresearch.c
® capsules ce undamageher encapsu
xtended she
small cell-baroduce bioacng “factoriesite of the tuand in effectis targeted c
EATMEN
oved in 199reatic cancecreatic cancea lot to be dsed in comb
nced, inoperation of the w
ion/
wguide/pancr
e 1: Cell-in-a-B
Sour
Invest
com
containing lived and approulation technlf life for the
ased factoriective therap
s” and their uumor as pot provide a dchemotherap
NT MARK
97, is still ther. Accordiner each yeaesired, a drubination withable pancre
widely used c
reatic-cancer-
Box Beads
rce: www.Pha
tment and O
COM
ve cells can oximately 95nology on the product as
es that can eutic substause in cance
ossible to crdramatically py in every s
KET
he only drugng to the Amar and 41,00ug called Abh gemcitabinatic cancer scancer drug
-overview-key
Image
armaCyteBiot
CompanyOpportunity
PANY R
be frozen a5% of the e
he market ths well as de
be made tances, and foer therapy, create a con
elevated dosense of the
g approved tmerican Can00 die from tbraxane®, pne. This comsince its app paclitaxel (
y-statistics
e 2: Prodrug
tech.com
y Researchy Research
REPORT
Page 4 of 17
nd stored foencapsulatedat has these
eployment to
to 1) converfor numerouscapsules withtinuous highose of active
e word.
to date as ancer Societythe disease.roduced and
mbination hasproval by theTaxol®) with
Cells
7
r d e o
rt s h h e
a y,
6 d s e h
Copyr
albuuse of pa
Resucomonly chemAbraincrefigurgemtreatpointthe h
CEL
The Phaspanconly (fromwas patieifosfaothetarge
For awerepancclinicdoubantitwith will com
7 http 8 http 9 http 10 httseco
right © Goldma
min and it hof the gemc
atients with t
ults from thbination rev
22% who motherapy saxane®.8 Toease in survres, one cacitabine for tment such t of view as hundreds of
LL-IN-A-BO
combinationse I/II trials ccreatic cance
drug approm 5.7 months
double thatents and noamide combr forms of ceted treatme
a second Pe published creatic canccal trial and ble that useumor effectitreatment. be used fomence in 2H
p://finance.yah
p://www.medic
p://www.firstw
p://www.pharnd-phase-2-c
an Small Cap R
as been a bcitabine/Abrathe disease
e pivotal Phealed that 3
just undersurvived for oo put this in vival rate, whn assume pancreatic cas PCMB’s the gemcitamillions.
OX® – EFF
n of the Ceconducted iner. When the
oved at the ts for Gemzat seen with o serious tbination. Thcancer was ent.
hase II trial in the med
cer have bee13 in the se
ed in the Phveness of thTherefore, tr future clin
H15.
hoo.com/new
calnewstoday
wordpharma.c
rmacytebiotecclinical-trial-ce
Research, 2015
ig seller, witaxane combincremental
hase 3 stud35% people rwent treatmonly 6.7 moperspective
hich is a mathat at simcancer is nepancreatic
abine/Abraxa
ECTIVE IN
ell-in-a-Box®n the early 2e data from time to trea
ar®) using thGemzar® (
treatment-rehis is becaus
used in this
more recendical journalen treated wcond Phase
hase I/II triahe treatmentthe combinanical trials.
ws/celgene-rep
y.com/articles
om/node/123
ch.com/nuvileell-boxr-plus-i
www.gold5
th $848 milliobination for ply as compa
dy used to on the combment with nths compae, the price ain reason wilar prices,
early $1 billiocancer treatane® combi
TRIALS
® technology2000s to be those trials t the diseas
he PMCB tre(18%). Tumlated side-ese only one-s Phase I/II
ntly led by thl Pharmacewith the Ce
e II clinical tril. Surprisint but it substation of Cell-
With this i
ports-fourth-q
s/255388.php
34052#axzz3U
ex-announcesfosfamide-co
dmanresearch.c
on in total capancreatic cared to gemc
obtain regubination wergemcitabinered to a metag for Abra
why the U.K. the market
on a year. Itment that mnation and i
y with the avery effectivwere compa
se), the medeatment andmor sizes weffects were-third the dotrial becaus
he same priutics. 10 Inll-in-a-Box®ial. For the s
ngly, doublinantially incre-in-a-Box® an mind, a f
quarter-full-12
Utv1TR5I
s-publication-cmbination-pa
Invest
com
ancer treatmcancer still ocitabine alon
latory approre alive at the alone. Thedian of 8.5 axane®, is has not apt size for at is not unre
may prove tois safer to u
anti-cancer dve in treatingared with hisdian surviva the one-yea
were also ree experiencose of ifosfase of the un
incipal invesn total, 27 p
®/ifosfamide second Phasng the dose eased the seand one-thirdfuture Phas
23000735.htm
combined-resatients-advan/
tment and O
COM
ment sales inonly increasene.
oval of the he end of thhose were months amoa hefty $28proved it for
a product useasonable tho be as effese might als
drug ifosfamg patients wstorical data al time was ar survival raduced from
ced using tamide normanique nature
stigator as tpatients witcombination
se II trial, the of ifosfamieverity of thed of the “no
se 2b trial i
ml
sults-initial-ph/
CompanyOpportunity
PANY R
n 2014,7 evees average
gemcitabinee first year solely on
ong those w8,000 a year sale.9 Bassed in conjherefore to pective from aso have a m
mide has beewith advance
for Gemzarincreased toate with trea25-50% in
the Cell-in-aally employee of the Ce
he previoush advancedn – 14 in the dose of ifode did not e side effectrmal” dose on Australia
hase-12-clinic
y Researchy Research
REPORT
Page 5 of 17
n though thesurvival time
e/Abraxane®compared togemcitabine
who also tookr for a smased on theseunction with
project that aan antitumo
market size in
en shown ined inoperabler® alone (theo 11 monthsatment (36%
4 out of 14a-Box® plused in treatingell-in-a-Box®
trial, resultsd, inoperablehe Phase I/Iosfamide wasincrease thets associatedof ifosfamideis slated to
cal-trial-
7
e e
® o e k ll e h a
or n
n e e s ) 4 s g
®-
s e II s e d e o
Copyr
ORP
The has panckey low-dtreat
OrphU.S.the availaver
Recemarktreatdesig
OT
Tranthe lfirst abilitascitpancgrosbrearemocan panc
An eelucislownext quar
In aunbeexpe
11 htt 12 htt
right © Goldma
PHAN DRU
Company’srecently be
creatic canplayer in thedose ifosfamtment of cho
han drug de, a rare diseU.S. pancrelable chemorage and the
eiving orphaketing exclutment for pagnation.11
THER CA
nslational Drleading authpreclinical sty of Cell-intes fluid procreatic as ws swelling o
athing difficuoved on a rebe quite ex
creatic cance
expanded sidate param
w down the atwo months
rter of 2015.
ddition, a Pearable andected to also
p://www.phar
p://finance.ya
an Small Cap R
UG STATUS
s flagship peen grantedcer. This dee anti-cancemide as a
oice for adva
signation in ease is defineatic canceotherapy, pae 5-year surv
an drug desusivity in thencreatic can
ANCER T
rug Develophority on pantudy (4 grou
n-a-Box® pluoduced by ell as other of the abdo
ulties and megular periodxpensive. Ier proved to
tudy (12 greters that waccumulatios. The target12
Phase 1 clind sometimeso start in the
rmacytebiotec
ahoo.com/new
Research, 2015
S
product for d Orphan Designation ser arena and treatment f
anced pancre
the U.S. is ned as one tr can be c
atients with avival rate is l
signation for e U.S. In adncer and exe
TREATM
ment (TD2),ncreatic canups of tumorus low-doseabdominal abdominal
omen that it may result indic basis; thin this first be effective
roups of micwill be neede
n of malignat date for the
nical trial uss untreatabthird quarte
ch.com/fda-gr
ws/pharmacyt
www.gold5
pancreatic Drug Statuserves as a mvalidates th
for advanceeatic cancer
given to druthat is diagnlassified asadvanced paess than sev
PMCB’s paddition, speemptions or
MENTS
, whose Chincer. PCMBr-bearing mices of ifosfamcancers. Tcancers cancauses ca
n new maligis is a difficupreclinical s
e in reducing
ce) is curreed for a futurant ascites fe initiation o
sing PMCB le pain fromr of 2015.
rants-orphan-
te-biotech-pro
dmanresearch.c
cancer, Ceby the FDA
major boost he use of theed inoperablr.
ugs or treatmosed in less a life-threaancreatic caven percent.
ancreatic caecial assistareductions i
ief DevelopmB recently rece) that wasmide combinThe accumun be very prn be very pnant tumors
ult process fostudy in theg the rate of
ently being cre clinical trifluid. It is ex
of the Phase
treatment fm advanced
-drug-designa
ovides-corpor
Invest
com
ell-in-a-Box®A for the trt to PMCB’s e Cell-in-a-Ble pancreat
ments for “ras than 200,0atening dise
ancer are de.
ancer treatmnce from thn regulatory
ment Officereferred to itss conducted nation to deulation of throblematic. problematic s being formor the oncoloe U.S of Ceaccumulatio
conducted bal that may xpected that
e 1 clinical tr
for advanced pancreatic
ation-nuvilex-p
rate-developm
tment and O
COM
® in combinreatment of developme
Box® technoic cancer w
are,” life-thre000 people inease becauestined to liv
ment carries he FDA in ty fees and ta
r is Dr. Danis very positiby TD2 in th
elay the acchis fluid thaIt is painful for patients
med. Thereogists, is paell-in-a-Box®
on of ascites
by TD2. Thresult in thet the study wrial on ascite
ed pancreatic cancer is
pancreatic-ca
ments-123000
CompanyOpportunity
PANY R
nation withf advanced,
ent efforts, sology in comwhich may
eatening disen the U.S. Inse, even w
ve less than
with it up tothe develop
axes can acc
iel Van Hoffve results frhe U.S. to dcumulation oat occurs inwhen it occ
s because iefore, this flainful for the ®, PCMB’s ts fluid.
his study is e only treatmwill be com
es in the U.S
ic cancer tos being plan
ancer-treatme
0857.html
y Researchy Research
REPORT
Page 6 of 17
ifosfamide, inoperabletanding as abination withbecome the
eases. In then addition, in
with the besone year on
o 7 years opment of thecompany the
f, is arguablyrom PMCB’setermine theof malignann those withcurs, and theit can causeluid must bepatients and
treatment fo
designed toment that canpleted in the
S. is the third
o control thenned and is
ent/
7
e, e a h e
e n st n
of e e
y s e nt h e e e d
or
o n e d
e s
Copyr
In Jua vemodCell-cancusedcomrefleCell-
“Basoverarisinchemof clevidecellstumocyclocytocnumtreat
It shsponpancconvthe ptolerof tucyclotwo reduredu
Therclinic
Constheretreatyearmultwom
13 htt 14 htt
right © Goldma
uly 2014, in tterinary Phael for breas-in-a-Box® pcer treatmend to treat mabination chect the poten-in-a-Box® te
sed upon prexpressing ng spontanmotherapeutlinical paramence of adv
s. Reductionours showiophosphamichrome P45
mber of dog mtment.”13
hould be nontaneously-ocreatic cancverted to thepancreatic arated in the umor shrinkophosphamitumors, the
uced by onlyuction in tum
refore, it is ecal trial that
sidering thae appears totment of brer is now a miple non-pro
men each ye
p://journals.p
p://www.brea
an Small Cap R
the medical ase I/II trial it cancer in hplus cycloph
nt, and the oammary canemotherapy ntially remarkechnology.
promising prcytochrome
neously in tic agents usmeters as wverse reactios in tumour ing minor ide alone sh50 expressinmammary tu
oted that reoccurring mcer trial. Howeir cancer-kilnd mammarmammary ckage were de versus th
e tumor thaty 14% whileor volume.
evident that tutilizes the C
t Celgene’s o be a clear
east cancer tmulti-billion dofit organizatear. As a res
los.org/ploso
astcancer.org/
Research, 2015
journal PLOn dogs bearhumans. Abhosphamidether dogs w
ncers in dogregimens u
kable results
reclinical st P450 enzydogs. The
sed for the twell as for ons or side size of moreresponses,
howed only ng cells comumours and
esults of theammary tumwever, sincling forms inry cancer stucancer trials,
observed inhose dogs ret did not ree the tumor
the results oCompany’s l
Abraxane®r relationshithat is diagn
dollar industrtions, etc.14 sult, when f
ne/article?id=
/symptoms/un
www.gold5
OS ONE, thering spontanbout 50% of
e, a “sister” were treated
s, is also usused to treats that can be
tudies, a clyme isoform
dogs weretreatment of reduction ineffects bein
e than 50% i.e. stabstable disea
mbined with support the
e aforementmors were e both cycl
n the same wudies. As in, with no man those doeceiving cyc
eceive encapreceiving e
of this animalive-cell enca
® was initiallp between e
nosed in 200ry unto itselfMoreover, b
firms gain ev
=10.1371/jour
nderstand_bc
dmanresearch.c
e Company aeously occuf the dogs indrug to thewith only cy
sed as one t breast cane achieved w
linical trial 2B1 were i
e then givmammary t
n tumour sizng associatewere observle diseasease. Taken
chemotherperformanc
tioned PMCremarkably
ophosphamway, the samn the human ajor safety isogs treated clophosphampsulated ce
encapsulated
l trial could lapsulation p
y approved efficacy of t0,000+ womf, highlightedbreast canceven modest
rnal.pone.010
c/statistics
Invest
com
announced vurring mammn this trial w
e ifosfamide yclophosphaof the comp
ncer in humwith PMCB’
was perforimplanted ar
ven cyclophtumours. Theze. The treed with the ved for 6 out. In contrtogether, th
rapy may bece of further
CB Phase I/y similar to ide and ifos
me type of epancreatic c
ssues. Impowith encap
mide alone. ells but reced cells plus
lead to a futuplatform.
for breast ctreatments foen and kills d by mammer appears tt success in
02061
tment and O
COM
very encouramary cancerswere treated that is par
amide. Cycloponents of thans. The rs treatment
rmed in whround malig
hosphamide,e dogs were
eatment wasadministrat
t of the 11 turast, the this data suge useful in clinical stud
/II clinical tits well-kn
sfamide areencapsulatedcancer trialsrtantly, sign
psulated ceIn the case
eived cyclopcyclophosp
ure success
cancer and or the two cover 40,000
mograms, othto be affectin
n their quest
CompanyOpportunity
PANY R
aging resultss. This is a with the co
rt of PMCB’ophosphamihe majority results of thof solid tum
hich encapsgnant mamm
one of the assessed fs well toleration of the eumours analtumours th
ggests that ethe local tre
dies to evalu
rial involvinnown humane “sister” drud cells were s, the capsulificantly grealls in combof a dog dia
phosphamidephamide sho
sful human b
then pancrecancers. Pre0 in the U.Sher tests, invng younger t for ever m
y Researchy Research
REPORT
Page 7 of 17
s obtained ingood anima
ombination os pancreaticide, normallyof multi-drugis dog study
mors using its
sulated cellsmary tumourshe standardfor a numbeated with noencapsulatedlysed while 5
hat receivedencapsulatedeatment of auate this new
g dogs withn Phase I/Iugs and areused in bothles were weater degreesbination withagnosed withe alone wasowed a 70%
breast cance
eatic cancerevention and
S. alone eachvolvement oand youngeore effective
7
n al of c y g y s
s s d
er o d 5 d d a w
h II e h ll s h h s
%
r
r, d h
of er e
Copyr
treatdisea
DIA
As encareprthereroom
AccoDiabglob
Sincmultindivand suffedam
Initiapancby th
To aimplausedbaseand use
PharencacellsrightAustBox®fulfillthe eline tinsul
A prdiab
15 htt
right © Goldma
tment for brease. Theref
ABETES
noted abovapsulation tresents an ee is no cur
m for impro
ording to a betes Drugs al diabetes m
ce the year 2iple daily inj
viduals with Tthe pancrea
er the serioage to the re
ally, in an efcreatic islet che body’s im
avoid such imantation. Hod in such stued capsulesthe insulin-pand/or supp
rmaCyte Bioapsulate insus. For Pharmts to a hutralia. Precl® technologl other criterevent that ththat meets alin-depende
roof of princetic animals
p://www.phar
an Small Cap R
east cancerfore, progres
S
ve, PMCB technology even larger re for diabe
ovement, as
report by Market – In
market for th
2000, effortsections of inType 1 disea
as cannot prous and debetinas of the
ffort to replacells were tr
mmune syste
mmune systeowever, the udies is often, agarose-baproducing caply of human
otech has aulin-producinmaCyte Biotman, non-pinical studiey, for their a
ria that will bese cells areall of the reqnt diabetes.1
ciple animal s, the anima
rmacytebiotec
Research, 2015
, their stockss in this trea
acquired thfor the deopportunit
etes and th anyone wit
Transparencndustry Sceherapeutic d
s have beennsulin to conase, the isleoduce the inbilitating cone eyes, kidne
ace the insuransplanted m.
em damagesuccess of
n agarose, aased capsulapacity of the or pig islet c
approached ng cells thattech’s initial pancreatic ces have beeability to probe required e not acceptquirements f15
study demoals’ elevated
ch.com/resea
www.gold5
s enjoy hugatment categ
he exclusiveevelopment ty for the cohe current ith insulin-d
cy Market Renario, Trendevices and d
n made to dntrol the bloot cells of the
nsulin requirensequences ey problems
ulin producininto humans
, islet cells fthis approac
a derivative oles have a re islet cells cells can be
these problt are not panefforts to decell line, kn designed
oduce insulinbefore they table for usefor encapsul
onstrated thd blood suga
arch-developm
dmanresearch.c
ge gains becgory could p
e worldwideof treatme
ompany thansulin repl
dependent d
Research, eds, Analysisdrugs is exp
develop treaod sugar levee pancreas hed to contro
of the diseand cardiac
ng cells of ths with Type
from humansch is somewof seaweed.rather limitedwithin such very proble
ems by decncreatic isleevelop a tre
known as Mto test thesn “on demacan be use
e, attempts wation and th
hat when cear levels be
ment/
Invest
com
cause of thepotentially pr
e rights to ents for diaan its curreacement te
diabetes wil
entitled ‘Glos, Size, Shapected to rea
atments for Tels of individ
have been del blood sugaease which c damage.
he pancreas1 diabetes,
s and from pwhat limited Comparedd lifetime in capsules is
ematic.
ciding to uset cells but raatment for TMelligen cese cells, aftend” under a
ed in humanwill be madehen can be u
ells that prodecame norm
tment and O
COM
e market sizerove to be w
use the cabetes. Thint cancer t
echnologiesll attest.
obal Diabeteare and Foreach US $114
Type 1 diabduals sufferiestroyed by
ar levels. Thinclude pe
s that had bbut these ce
pigs have bebecause the
d to PharmaCthe body adifficult to m
se the Cell-iather genetiType 1 diabeells, developer encapsulaa variety of cs; these stu
e to develop used in clini
duce insulinmalized and
CompanyOpportunity
PANY R
e and high worth substan
cellulose-bas treatmenreatment ins certainly
es Devices ecast, 2011 4.3 billion by
betes that dong from thisan autoimm
hus, such indripheral ner
been destroyells were soo
een encapsue encapsulaCyte Biotechnd need to
maintain. In
n-a-Box® tecally engineetes, it has ped by resation using tconditions, a
udies are in an insulin-pcal trials in
n were transremained s
y Researchy Research
REPORT
Page 8 of 17
profile of thential sales.
sed live-cent categorynitiatives, asleave much
Market and- 2018,’ the
y 2018.
o not involves disease. Inmune diseasedividuals canrve damage
yed, “nakedon destroyed
ulated beforeation materiah’s cellulosebe replacedaddition, the
echnology toeered humanobtained the
searchers inthe Cell-in-aas well as toprogress. Inroducing cehumans with
splanted intotable for the
7
e
ll y s h
d e
e n e n
e,
” d
e al e-d, e
o n e n -o n ll h
o e
Copyr
durato thhavediab
Armeinitiaproficellu
Studnon-cellstheirPCMfromthe dhas InstitMelli
CA
With(canthe gsuchin coand
It haand cannagenmodin coa-Bo
Initiaof Ndevecurrea suthe ithe c
16 htt
right © Goldma
ation of one she higher thae acted as
betes.
ed with thesation of humle. PMCB is
ulose-based
dies are in pr-pancreatic, s (human, nor surroundingMB formed am institutions
developmenbeen appoitute for Vasigen cells du
ANNABIN
h the relaxanabinoids) fgrowing, proh activities. ombination wdeadly disea
as been knowvomiting tha
nabinoids fonts against el systems.
ombination wox® plus ifos
al efforts to dNorthern Coeloped thereently being mitable cell tyifosfamide-acannabinoid
p://finance.ya
an Small Cap R
six-month stan normal b
an artifici
se valuable man clinical ts clearly notlive-cell enc
rogress at thinsulin-prod
on-pancreatigs. To facili
a Diabetes Cin several ct of Pharmanted Directoscular Invesuring her pre
NOID RE
ation in manfor medicinaoduction, salRather, Phawith the Celases; these
wn for manyat are assocor such purpa wide varie PharmaCyt
with the Cell-sfamide com
develop sucolorado, fune for the semade to idenype cannot bactivating ce-like candida
ahoo.com/new
Research, 2015
tudy. This evlood glucosal or repla
study resutrials which,t a “one-trickcapsulation t
he Universityducing) cellsc, insulin-prtate all of th
Consortium tcountries. PaCyte Biotecor of the Diastigation andevious tenure
ESEARC
ny states inal purposes, es and/or m
armaCyte Bil-in-a-Box® include brai
y years that iated with so
poses. Moreety of cancete Biotech b-in-a-Box® t
mbination will
h treatmentsnded by Pheparation ontify a type obe identifiedells were devates have be
ws/pharmacyt
www.gold5
vent indicatee levels in t
acement pa
lts, manage, in turn, wilk pony” andtechnology in
y of Veterinas do not prooducing) ca
he studies thhat includes
Participants ich’s treatmeabetes Resed Treatmente with PCMB
CH
n the U.S. omany entiti
marketing of otech will atencapsulatin cancer an
Cannabis anome forms oe recently, cer types in
believes that technology al be used to
s have beenharmaCyte f cannabino
of cell that ca, one will beveloped for een identifie
te-biotech-pro
dmanresearch.c
es that the ethe animals.ancreas wh
ement will lill serve to s
d now has mn developing
ary Medicineoduce tumorn produce ahat will be ns prominent n the Diabent for insulinearch Progrt (VIVIT) in B’s partner, A
of rules agaes have emCannabis. ttempt to uson technolod pancreatic
nd cannabinof cancer. Tcannabinoidpreclinical scannabinoid
as cancer tretreat pancre
n under wayBiotech. Aoids and caan activate s
e designed bPharmaCyt
ed and the a
ovides-corpor
Invest
com
encapsulated Therefore,
hich has tre
kely take stsubstantiallymultiple shotg treatments
e, Vienna to rs and to esand store insneeded befoinvestigators
etes Consortn-dependentram. Dr. Bra
Austria, waAustrianova
ainst the usmerged over
PharmaCytese cannabinoogy to develoc cancer.
noids can beThere are drus have beestudies in thds or cannaeatments in eatic cancer
y for some tiAlready, “staannabinoid-lsuch compoby gene trane Biotech’s
appropriate c
rate-developm
tment and O
COM
d cells prodthe encaps
emendous
teps that wy raise the cts on goal ws for both dia
determine thstablish parasulin in respoore clinical trs experiencetium will be t diabetes. Dandtner, preas responsi
a, as its Chie
se of Cannthe recent p
e Biotech wioids or cannop “targeted
e useful for tugs already
en shown tohe laboratorbinoid-like cmuch the sa.
me by reseaate-of-the-artike compou
ounds to theinsfection in m
pancreatic cells have be
ments-123000
CompanyOpportunity
PANY R
uced insulinsulated cellvalue in tr
ill ultimatelycompany’s vwith the rightabetes and c
hat the Melliameters by onse to glucrials can be ed in the diainvolved in aDr. Eva-Mar
esently at thble for stud
ef Scientist.16
nabis or its past that areill not be invnabinoid-liked” treatment
reating the pon the mark be effectivry and in ancompounds mame way tha
archers at tht” methods
unds, and air cancer-killmuch the sacancer treaeen develop
0857.html
y Researchy Research
REPORT
Page 9 of 17
n in responsels appear toreatment o
y lead to thevalue and itsts to use thecancer.
gen (humanwhich these
cose levels inundertaken
abetes arenaall phases oria Brandtnee Vorarlberg
dies with the6
constituentse involved involved in anye compoundss for serious
pain, nauseaket based one anticancenimal cancemay be usedat the Cell-in
he Universityhave been
attempts areling forms. Iame way thatment. Once
ped, the cells
7
e o
of
e s e
n, e n
n, a of er g e
s n y s s
a n r
er d -
y n e f
at e s
Copyr
will bsyste
The of inand firm reacinclucannLöhrgastexpeCom
UP
The full (the rPhasin thpanc(a re(CNSPhas
It shfor hpremreguOnceadvainspe
Sepayear
17 htt
right © Goldma
be encapsulems (of brai
medical mavestors andas more staSea Chang
ch $8.9 billioude Dr. Manabinoid-basr of the roenterologi
erience withmpany’s goal
PCOMING
next few monot just prelresults are sse 1 trial to ce U.S. In th
creatic cancecipe for conS) - one of se 2b clinica
ould be notehuman clinicmier biotechulatory authoe the facilityanced pancection/appro
arately, we ar as well.
p://www.phar
an Small Cap R
ated using tn and pancr
rijuana arend entrepreneates pass mege Strategy on by 2016.ark Rabe ansed disease
famed Kst/oncologis cannabinois.
G MILES
onths could iminary) ressolid, as wecontrol the uhe meantimeer are ongonducting theAustralia's
al trial in Aus
ed that the ecal trials has location, t
orities to ensy is deemed creatic cancoval process
anticipate m
rmacytebiotec
Research, 2015
the Cell-in-areatic cancer
na is enjoyingeurs as manedical marijuestimates th. PCMB is nd Dr. Garrtreatments.
arolinska st will play ids, cancer
STONES
see some oults from the
e expect, a unbearable pe, preparatioing. Major d
e clinical trialeading Clin
stralia is the
encapsulatios been comhe Thai Sc
sure that it csatisfactory
cer and it s should be c
meaningful p
ch.com/
www.gold5
-Box® and tr, for examp
g a great dey prognosticuana legislathat the U.S.building an et Yount, b Other memInstitute ina major rodrugs and
S
of the most e preclinical Phase 1 triapain from adons for the Pdocuments, al) are in prenical Researthird quarter
on facility thapleted and
cience Parkomplies with
y, then produdebilitating
completed in
rogress on t
dmanresearch.c
the combinale) that are a
eal of attentiocators forecation. For exa medical maimpressive oth of whommbers of then Stockholole in the enzymology
significant eascites fluid
al could comdvanced panPhase 2b cliincluding theeparation, wrch Organizr of 2015.
at will preparsuccessfully. The facih current Gouction of the
symptomsn the third qu
the diabetes
Invest
com
ations will beavailable to
on, a high mast huge revample, the inarijuana maScientific A
m will play e Scientific Am, Swedecompany’s
y could prov
events in Cod study curremmence latencreatic cancinical trial ine Investigato
with the assiszations. The
re the Cell-iny tested in Bility is beingood Manuface Cell-in-a-Bo can commuarter of 201
s and canna
tment and O
COM
e tested in aPharmaCyte
market valuatvenue growtndependent arket is wortAdvisory Boa
major rolesAdvisory Bo
en and afuture end
ve to be inv
ompany histently underwer this year.cer. It too w
n patients wiors Brochurstance of Ctarget date
n-a-Box® caBangkok, Thg prepared cturing Pracox® capsulemence. It 15. 17
abis fronts in
CompanyOpportunity
PANY R
ppropriate ae Biotech.
tion and a grth over the financial ne
th $1.7 billioard, and this in the devoard, led by n eminent
deavors. Tvaluable in p
ory. In 1H15way at TD2 i The same
will be conduth advanced
re and a clinClinical Netwe for the init
apsules thathailand at thfor inspect
tices (cGMPes for the cli
is expecte
n the second
y Researchy Research
REPORT
Page 10 of 17
animal mode
rowing cadrenext 3 years
ews and dataon and couldis Board wivelopment oDr. Matthias
t EuropeanThat Board’spursuing the
5, we expecn the U.S. Iis true for a
ucted by TD2d, inoperablenical protoco
work Servicestiation of the
t will be usedhat country’stion by drugP) standardsnical trials ined that the
d half of this
7
el
e s a d ll
of s n s e
ct f a 2 e ol s e
d s g s. n e
s
Copyr
MA
Overin scmemshap
Kenthe
KennMr. BrobbioteHe wExecBrobWag
FurthcomprofeCounserv
right © Goldma
ANAGEM
r the past yecientific role
mbers of the ping direction
nneth L. WBoard
neth L. WagWaggoner s
beck, Phlegeechnology cwas the Macutive Commbeck’s worldggoner was t
her highlightpanies durinessional carensel of its Gices to the N
an Small Cap R
MENT
ear, PMCB ls. Plus, othDiabetes Con of the Com
aggoner –
ggoner has astarted his cer and Harlients includ
anaging Partmittee for adwide operathe Co-Chai
ts of Mr. Wang the last seeer. During lobal Downs
North Americ
Research, 2015
Sou
eadership her distinguisonsortium a
mpany.
– Chief Exe
almost four career as arison, nameing Chiron, tner of Brobalmost ten yations with arman of Bro
ggoner’s caeveral yearshis tenure wstream operacan, Latin Am
www.gold5
Figure 1: Rurce: www.P
has undergoshed scientind the Com
ecutive Off
decades of an attorney ed one of tAmgen, Bio
beck’s Los Ayears and annual revebeck’s world
reer include s as well as wwith Chevronations wheremerican, Eu
dmanresearch.c
&D Pipeline harmaCyteB
ne a makeosts and docpany’s Scien
ficer, Pres
experience in private phe top two ogen Idec, SAngeles offion the Poli
enues in exd-wide Envir
leadership aworking with, Mr. Waggo
e he was resrope and As
Invest
com
e Stages Biotech.com
over, with thectors, such ntific Adviso
ident, Gen
in managempractice. Not
law firms wSangamo, Lice. Mr. Waicy Committ
xcess of $75ronmental La
and legal poh Fortune 50oner served sponsible forsian Product
tment and O
COM
m
e addition ofas Dr. Van
ory Board wi
neral Coun
ment, businetably he waworldwide tigand, Depo
aggoner wastee for num50,000,000. aw Group.
ositions with 00 companie
as the Vice r the overall ts Companie
CompanyOpportunity
PANY R
f multiple, keHoff and D
ll play signif
nsel and C
ess, operatioas a senior that provideoTech and ms also a memerous year
While at B
several stares most of hi
President amanageme
es. At Chevro
y Researchy Research
REPORT
Page 11 of 17
ey personneDr. Löhr, andficant roles in
hairman o
ons and lawpartner with
e services tomany othersember of thers managingBrobeck, Mr
rt-up s
and General ent of legal on he led a
7
el d n
f
w. h o s. e g r.
Copyr
succTexain Lo
Ger
Dr. Cvarioof mreviethe Athe Nincepfromman
Dr. Chas FelloInstitUniv(OncCorpdevepanc
Prof
ProfAs wexpeNordbiotedeveDoppmem
ProfgeneAssoreguPaulpublNatuco-aof a cont
right © Goldma
cessful restruaco. Mr. Wagos Angeles.
ald W. Cra
Crabtree is ous biopharm
multiple drugew articles aAmerican SoNational Instption, a dep
m initial discoager for the
Crabtree recpublished ov
ow. In additiotute, and pri
versity. Dr. cology/Immuporation. Moeloping a trcreatic cance
f. Dr. Walte
. Walter H. Gwell as beingerience in thdic, from 199ech companeloped/are dpler Labora
mber of ViruS
. Gunzburg e therapy aociation’s Culatory agencl Ehrlich Insished more
ure, The Lanuthoring thenumber of
inues to be a
an Small Cap R
ucturing of thggoner rece
abtree, Ph.D
the Compamaceutical cg candidatesand served aociety of Clintitute of Heaartment that
overy througdevelopmen
ceived his Phver 80 articleon, he serveor to that as
Crabtree unology) at Bost recently,reatment thaer.
er H. Günz
Gunzburg is g a full Profee biotech in94-2001 and
nies, Paktis eveloping atory for Ge
Sure, a virus
has been as well as xentral Comcies includinstitute, Langthan 130 p
ncet, Proceee first Germaf internationan active rev
Research, 2015
he companyeived his Juri
D. – Chief
any’s Chief companies ws, prepared as project mnical Oncoloalth and the t monitored
gh regulatorynt of the ant
h.D. in Bioches in peer-reed as Depars Associate P
has alsoBristol-Myers Dr. Crabtreat was bas
zburg – Chi
the co-founessor of Virodustry. He wd was involvand Liponovdvanced mene Therape
s and prion te
actively involxenotransplamission for g the US FDgen, Germa
peer-revieweedings of thean languageal cell and viewer for m
www.gold5
y’s internatiois Doctorate
Operating
Operating Owhere he has
clinical protanager for d
ogy and alsoAmerican Cand coordiny approval iicancer age
hemistry fromeviewed jourrtment HeadProfessor of
o served s Squibb andee served ased on a tr
ief Scientif
der, Chairmology at the Uwas a scientved in their va, as well edicinal treateutic Vector esting comp
lved in Euroantation for
Somatic GDA, EMA, TGany. Prof. Ged publicatioe National Ace textbook on
gene theramany top tier
dmanresearch.c
nal Legal Dee with honors
Officer an
Officer. Sincs alternativetocols, invesdevelopmeno is a past mCancer Socienated the den a major pnt, Taxol®.
m the Univerrnals. He is ad of Moleculaf Medicine was Directod as Vice-Pras Interim Craditional Ch
fic Officer
man of the BoUniversity oftific advisor IPO. He haas the U.S
tments for cDevelopme
pany located
opean ethicsmany years
Gene TherapGA, HSA anGunzburg coons in interncademy of Sn gene thera
apy journals journals as
Invest
com
epartment fos in 1973 fro
nd Director
ce 1985, Drely supervisestigator broct of major o
member of reety. Dr. Crabevelopment opharmaceutic
rsity of Albea National Car Pharmaco
with the Rogor of Projresident of R
CEO of Phythinese med
oard and Chf Vienna sinto the intern
as also beenS. biotech cocancer. He went from 20 in Vienna th
s and regulas. He was apy. He has d Thai-FDA ontinues to national scieSciences USapy. He is a
including Twell as gran
tment and O
COM
ollowing Cheom Loyola U
r
r. Crabtree ed and coordchures, monncologic age
esearch granbtree establiof oncologiccal compan
rta, EdmontoCancer Institology for theer Williams ect Planni
Research antoCeutica, I
dicine herba
hief Technicance 1996, henational vacn a scientificompany, Towas also the 003-2011. Chat he cofou
atory affairs a member also interaand was onbe an acti
entific and mSA and Canalso a membTrends in Mnt funding ag
CompanyOpportunity
PANY R
evron’s acquniversity Sch
has been indinated the dnographs, reents. He is ant review coished and d
c and immuny and serve
on, Alberta, ute of Canade Nucleic AcCancer Cenng and M
nd Developmnc., a biote
al formula f
al Officer of e has had mccine compac advisor to cagen Inc., Director of t
Currently, heunded.
in the fieldsof the Germ
acted with an the review ve research
medical journcer Researcber of the edMolecular Mgencies.
y Researchy Research
REPORT
Page 12 of 17
uisition of hool of Law
nvolved withdevelopmenesearch anda Member o
ommittees foirected, from
nologic drugsed as projec
Canada andda Researchcid Researchnter at BrownManagemen
ment at ETEXech companyfor liver and
Austrianovamany years o
ny, Bavarianthe Germanall of which
the Christiane is a board
s of cell andman Medicaa number opanel for theher and hasnals such asch as well asditorial boardedicine, and
7
h nt d
of r
m s
ct
d h h n nt X y d
a. of n n h n d
d al of e s s s d d
Copyr
Dr. E
FolloGenAustfor gcancAustlive respBranencaDr. Bioe
Dr. BprepjournmeeGen
Dr. M
Dr. MPrinctreatencaactudosepancdeveLöhrtech
Dr. LSweHeadsciencomFollomedProfeadditCanc
right © Goldma
Eva-Maria
owing receipetics in 200trianova Biogene therapycer at the trianova Ptecell Bioencaonsible for a
ndtner was iapsulation inBrandtner
encapsulatio
Brandtner isparation. Shnals and htings. Dr. Be Therapy.
Matthias L
Matthias Löhcipal Investigtment that wapsulation teally adminis
es of the wecreatic cancelopment of r has expertinology and
Löhr is Proden. He hasd of a divisntist and Prpleted a poowing receipicine and gessor. Dr. Lötion, Dr. Löcer Researc
an Small Cap R
Brandtner
pt of her Doc01, Dr. Bramanufacturiy. In 2007, same comp Ltd (Austriaapsulation. all encapsulaintimately in
n developingleft Singapon Unit at the
s co-inventoe has co-auas presente
Brandtner is
Löhr – Scie
hr is the Chgator for thewere compleechnology thstered Pharmell-known a
cer. Dr. Löhtreatments se in the treits use in a c
fessor of gas also servesion at the rincipal Inveostdoctoral fpt of his medgastroenteroöhr holds a
öhr is a Memch Centre, H
Research, 2015
r – Director
ctorate in Naandtner servng AG in AuDr. Brandtnepany. Shoranova) wherThis was f
ation projectnvolved in ag a treatmenore to retu
e Vorarlberg
r on two grauthored numed researcha member o
entific Advi
hairman of the Phase 1/2 eted in the hat forms thmaCyte Biotnticancer drr is also sefor pancrea
eatment of boclinical settin
astroenteroled as ProfesGerman Ca
estigator in fellowship adical degreeology in ErlaPh.D. and amber of Clineidelberg, G
www.gold5
r of Diabet
atural Sciencved as a Pustria whereer became Prtly thereaftere she oversfollowed in 2ts in medicinll of the pre
nt for insulin-urn to Aust
Institute for
anted patenerous reseah results aof the Europ
isory Boar
he PharmaCand Phase early 2000s
he core of Ptech’s treatmrug ifosfamiderving as a atic cancer aoth diseasesng.
ogy and hessor of Moleancer Reseaclinical stud
at the Scripe, Dr. Löhr sangen and
an M.D. fromnical Coope
Germany.
dmanresearch.c
tes Progra
ces in the arPostdoctoral e she was inProject Maner, Dr. Brasaw the dev2010 by hene and bioloeclinical wor-dependent tria where Vascular Inv
nts and is naarch reports at national ean Society
rd Chairma
Cyte Biotech2 clinical tri
s. Not only PharmaCyte ment (the code) in clinicconsultant
and diabetes in addition
epatology atecular Gastroarch Centerdies in gastps Clinic &
served a resRostock in
m the Karolineration Unit
Invest
com
m Develop
reas of BiocScientist a
nvolved in thnager for woandtner wasvelopment ofer promotionogy. Most imrk done therdiabetes. Dshe is curvestigation a
amed on sethat have band interna
y for Gene T
an
h Scientific Aials of Pharmis he familiBiotech’s p
ombination ocal trials in to PharmaCs based on to thorough
t the famedoenterology . Dr. Löhr hrointestinal Research
sidency in pan Germany, nska Universof Molecula
tment and O
COM
pment
chemical Micand Senior he developm
ork on the ces promoted f numerous n to Chief Smportantly, wre that invoDue to familrrently empand Treatme
everal additieen publisheational scie
Therapy and
Advisory BomaCyte Biotiar with the
pancreatic caof Cell-in-a-Bpatients witCyte Biotech
the Cell-in-hly understan
d Karolinskaat the Univ
has also wooncology foFoundation
athology andwhere he
sity Hospitalar Gastroen
CompanyOpportunity
PANY R
crobiology anPostdoctora
ment of retroell-based the
to Senior projects con
Scientist at while at Auslved the usey commitmeloyed as Hent (VIVIT).
ional patented in reputa
entific confe the Austria
oard. Dr. Löhtech’s pancrCell-in-a-Bo
ancer treatmBox® capsuth advancedh in connec-a-Box® tecnding the Ce
a Institute inersity of Heorked as a or many yea
in La Jollad a residencwas also a
, Stockholmterology at
y Researchy Research
REPORT
Page 13 of 17
nd Moleculaal Fellow aoviral vectorserapy of live
Scientist ancerned withAustrianova
strianova, Dre of live ceents, in 2012Head of the
s that are inable scientificerences andn Society fo
hr served asreatic canceox® live ce
ment, he hasules with lowd, inoperablection with itschnology. Drell-in-a-Box®
n Stockholmidelberg andtranslationa
ars and hasa, Californiacy in internaan Assistan, Sweden. Inthe German
7
ar at s r
at h
a, r. ll 2 e
n c d r
s er ll s w e s r. ®
m, d al s
a. al nt n n
Copyr
RIS
As istrialstrialsfar, beliethesothe
VA
In ouare biotetens GivedrugbiggRNNplethmind
Invesdevea maCleatermexistof athera
Table
Comp
Globe
Incyt
Merr
NewL
Rexa
Thres
Avera
Pharm
Celge
Sourc
right © Goldma
SKS
s the case ws and studies are the gremajor addit
eve managee strengths.r related iss
ALUATIO
ur view, baseundervalued
echs tend toof millions
en its combigs into their est treatmen
N), which rechora of goodd, we believe
stors shouldelopment, tharket cap of arly, as miles
m, the very nting therapiection, the hapy. Therefo
e I. Pharmacy
pany Name
eImmune
e
imack Pharmac
Link Genetics
hn Pharmaceut
shold Pharmace
age
maCyte Biotech
ene
ce: www.Yahoo
an Small Cap R
with most mes and acceseatest overaions in leadment does i. Risks assoues. All of th
ON AND
ed upon thed. As evideo trade baseassociated ination targecancer killinnt markets, Pcently raisedd news and e the shares
d note that ey traded atunder $300
stone eventsnature of thes. Thereforehighly conceore, we may
te Biotech Mi
Sym
GB
INC
ceuticals MA
NLN
ticals RN
euticals TH
h PM
CE
o!Finance.com,
Research, 2015
mid-stage bioss to capita
all risk to thedership and ndeed haveociated withhese risks ar
CONCL
valuations oenced by thed upon milewith variouseted therapyg form andPMCB has md funds for dmultiple tria
s could reach
two years at much lowe
0M versus ths occur, PM
he PMCB dee, it may ultentrated andy be witness
id‐Stage Panc
mbol Price (3/1
IM $8.15
CY $97.08
ACK $12.08
NK $55.93
NN $0.70
LD $4.53
MCB $0.11
LG $125.3
Goldman Smal
www.gold5
otechs, the l to commeese shares a
validation o access to t
h PMCB tradre typical of
LUSION
of the peer ghe market cestone deves stages. Pluy with uniqu the potentia
more in its codevelopmenals in the offh $0.45 whe
ago, when er valuationshe current $1CB sharehoelivery platfoimately be ud targeted ing the dawn
creatic Cancer
18/15) 52‐wk h
5 $15.0
8 $97.1
8 $12.5
3 $56.7
0 $1.35
3 $5.41
1 $0.49
33 $125.5
ll Cap Research
dmanresearch.c
major risks nce and conand other bof the technhe capital neding as a nfirms PMCB
group belowaps of the
elopmental eus, certain aue encapsual of its use orner than ht. Ironicallyfing near tern the Phase
some of thes. For examp1.6B valuatioolders could orm and itsused to treatplacement cn of a new u
Peer Group
high 52‐wk l
00 $4.29
3 $40.30
0 $4.13
9 $17.32
5 $0.65
1 $2.58
9 $0.10
58 $66.85
Invest
com
to these shnduct these iotech stocknology mitigecessary to on-NASDAQ
B’s size and
w, and PMCBcompanies
events and sapproaches lation techn as a univer
higher valuaty, the stock irm which one IIb trial com
ese companple, New Linon! Merrimaalso be stro
s therapeutict multiple forconcept, an
universal the
low Mkt Cap
9 $46
0 $1,66
3 $1,29
2 $1,59
5 $125
8 $323
$840
0 $77
5 $100B
tment and O
COM
hares includetrials. Of co
ks. Howevegate many o
conduct neaQ security cstanding.
B’s current sin the tablesize of the can be valu
nology that rsal therapy tion peers suis trading ne
nly enhance mmences in
nies were nnk Genetics ack, a solid pongly rewardc indicationsrms of canc
nd low toxicerapy for mu
(mil) Clin. Sta
Phase
67 Phase I
90 NDA Pr
90 Phase II
5 Phase
3 Phase
0
Phase
B Approv
CompanyOpportunity
PANY R
e delays in ourse, poor
er, given theof these riskar term trialscan include
standing, PMe below, pumarket oppoued greater activates chin the healt
uch as Rexaear year lowvaluations. 3Q15.
not as far a(NASDAQ –peer, is up nded. Lookins are uniqu
cer given thecity associatltiple diseas
age M
e I Immu
II, I Target
rep Enca
I,III Immu
e I Target
III Target
II Tgtd, En
ved Chem
y Researchy Research
REPORT
Page 14 of 17
launching oresults from
e results thusks. Plus, wes because oliquidity and
MCB’s sharesublicly tradedortunity, withthan others
hemotherapyth care fieldsahn (NYSE –
ws despite its With this in
long in thei– NLNK) hadnearly 300%ng out longee relative to
e mechanismted with thees.
Method
unotherapy
ted Inhibitor
apsulation
unotherapy
ted Inhibitor
ted Prodrug
ncap, Prodrug
motherapy
7
of m s e
of d
s d h s. y s – s n
r d
%. er o m e
Copyrright © Goldmaan Small Cap R
RECENT
Research, 2015
TRADING
www.gold5
HISTORY
(Source: w
dmanresearch.c
FOR PHA
www.BarCha
Invest
com
RMACYTE
rt.com)
tment and O
COM
E BIOTECH
CompanyOpportunity
PANY R
H, INC.
y Researchy Research
REPORT
Page 15 of 17
7
Copyr
SEN
Rob comDurinComGrowboutSma
Ana
I, Romy pis, or
Disc
This
GoldforminterreposponResethe sprofiupsidreseelimia pe
Gold
The we nmakor otits fcomand
SepaopinComConsshouand
right © Goldma
NIOR ANAL
Goldman fopany researng his tenure
mmunicationswth Researctique investmall Cap Grow
lyst Certific
obert Goldmapersonal viewr will be, dire
claimer
Opportunity
dman Small mats: Goldmarnally generaorts, updatesnsored microearch categosame coveraled stocks inde. Goldmanarch subscrinate pecunir report bas
dman Small
information neither guare an indepether firms. Gfilings, presspleteness. Suncertaintie
arate from thions about t
mpany are sostitution, anuld not be cthe opinions
an Small Cap R
LYST: ROB
ounded Goldrch experiene as a sell ss teams. Prioch Group. In ment managwth portfolios
cation
an, hereby cws about theectly or indire
y Research r
Cap Researan Select Reated stock ids and Micrococap researcory. It is impage criteria in the Opportn Small Capription serviciary interestsis and not on
Cap Resear
used and srantee nor rndent invest
Goldman Sms releases, Statements hs affecting re
he factual cothe Companolely our ownd are provi
considered tos expressed
Research, 2015
BERT GOL
dman Small Cce as a seniide analyst, or to joining addition to hement firm a
s and The Bl
certify that the subject secectly, related
report was p
rch, (a divisioesearch and deas along wcap Hot Topich ideas tha
portant to notn determinintunity Resea
p Research wce. Our analys, retain editn the basis o
rch is not aff
statements orepresent thtigation or inall Cap Rese
presentatioherein may esults.
ontent of ourny, its businn, and are mded solely o be compleare subject
www.gold5
LDMAN
Cap Researior researchRob was a sPiper, Rob his sell-side and Blue andlue and Whit
he view exprcurities and d to the reco
prepared for
on of Two TGoldman O
with economcs articles ret typically cate that whileng coveragearch format twas compenysts are resptorial controlof his/her rec
filiated in any
of fact madehe completenquiry as to tearch relied ons, and thcontain forw
r articles aboess, market
made in reliafor the genete, preciseto change w
dmanresearch.c
rch in 2009 a analyst andsenior memled Josephthexperience
d White Invete Fund.
ressed in thisissuers. I als
ommendatio
informationa
riangle ConsOpportunity R
ic and stockeflect sponsarry greater re we may tra of all stockstypically havnsated by a tponsible only, and ensurecommendati
y way with G
e have beenness or accthe accuracysolely upon
hrough its oward-looking
out the Comts and oppoance upon oueral opinion, accurate, o
without notic
Invest
com
and has oved as a portfober of Piper hal & Co.'s WRob served
estment Man
s research rso certify thans or views
al purposes
sulting GrouResearch. Thk market outlsored (paid) risks than th
ack performas in both res
ve a higher rithird party iny to the pube independeions.
Goldman Sa
n obtained frcuracy. Goldy of any info
n informationown internag statements
pany, we maortunities. Anur rights undnated discusor current ine.
tment and O
COM
er 20 years oolio and mutu
Jaffray's TeWashington-d as Chief Invnagement, w
report or artiat no part ofexpressed i
only.
up, LLC) prodhe Select folooks. Opporesearch bu
hose stocks ance separatsearch formaisk profile, an the amounlic, and are
ence. Analys
chs & Co.
rom sourcesdman Smallormation pubn published bal due diliges and are su
ay from timeny opinions der the Firstssion of ournvestment a
CompanyOpportunity
PANY R
of investmenual fund manechnology an-based Emevestment Of
where he ma
cle, accuratef my compenn this resea
duces researmat reflectsrtunity Reset can also incovered in ttely, we utilizats. Researcand may offet of $4000 fopaid in advasts are comp
s consideredl Cap Reseblished by thby the Compence for acubject to sig
e to time inclwe may off
t Amendmenr readers. O
advice. Such
y Researchy Research
REPORT
Page 16 of 17
t and nager. nd
erging fficer of a
anaged
ely reflect nsation was,rch report.
arch via two s the Firm’s earch nclude non-he Select ze many of
ch reports oner greater or a ance to pensated on
d reliable buearch did nohe Companypany throughccuracy andnificant risks
lude our ownfer about thent to the U.SOur opinionsh information
7
n
ut ot y, h d s
n e
S. s n
Copyr
A Gsolicaccopublinvesof thbrokstate
ALL IMPLAPPQUAFORMAYNOTTHAFULLIABPROINFO
For m
right © Goldma
Goldman Smcitation of anount the invication doesstment. Anyhe risks menker-dealer ore securities r
INFORMATLIED, OR R
PLICABLE LALITY, ACCR ANY DIREY ARISE OUT LIMITED AT MAY RES
LEST EXTEBLE TO YOUODUCTS LORMATION.
more inform
an Small Cap R
mall Cap Ren offer to buyvestment obs not providey discussion ntioned. Ner an investmeregulatory au
TION IN THREPRESENTLAW, TWO URACY, COCT, INDIRE
UT OF THE TO, LOST
SULT FROMENT PERMIU OR ANYOIABILITY, .
ation, visit o
Research, 2015
esearch repy or sell the bjectives, fine all informatof risks in thither Goldment adviser wuthority.
IS REPORTTATIONS OTRIANGLE
OMPLETENECT, CONSE
USE OF THPROFITS,
M ANY INACITTED BY L
ONE ELSE UOR OTHE
our Disclaime
www.gold5
ort or articlsecurities m
nancial situation materialhis presenta
man Small Cwith FINRA,
T IS PROVIDOF ANY KINE CONSULTNESS, RELIAEQUENTIALHIS INFORMLOSS OF OCURACY OLAW, TWO UNDER ANYR THEORY
er: www.gold
dmanresearch.c
e is not intmentioned oation, or pal to an inves
ation is not aCap Researc
the U.S. Se
DED “AS ISND. TO THTING GROABILITY ORL, INCIDENTMATION BYOPPORTUN
OR INCOMPLTRIANGLE
Y TORT, COY WITH R
dmanresearc
Invest
com
tended as aor discussedarticular neestor’s decisioa disclosure ch, nor its pecurities and
S” WITHOUTE FULLESTUP, LLC W
R TIMELINETAL, SPECIAY YOU OR ANITIES, TRALETENESS
E CONSULTONTRACT, RESPECT
rch.com
tment and O
COM
an offering,. This publiceds of any on about wheof all risks o
parent, is red Exchange
T WARRANTT EXTENT WILL NOT ESS OF THAL OR PUNANYONE EADING LOSOF THIS IN
TING GROUNEGLIGENTO THIS
CompanyOpportunity
PANY R
recommencation does
particular pether or not or a completegistered as
Commission
TIES, EXPRPERMISSIBBE LIABLE
HIS INFORMNITIVE DAMA
LSE (INCLUSSES, ANDNFORMATIOUP, LLC WICE, STRICT
PRESENT
y Researchy Research
REPORT
Page 17 of 17
ndation, or anot take intoperson. Thisto make any
te discussiona securities
n or with any
RESSED ORBLE UNDERE FOR THEMATION, ORAGES THATUDING, BUT
D DAMAGESON). TO THEILL NOT BET LIABILITYTATION OF
7
a o s y n s y
R R E R T T S E E Y, F
